Get in touch today 206.598.4100 or

Schedule an Appointment

Peter Goff, MD, PhD

Acting Instructor


Dr. Goff is a physician scientist treating patients with skin and head & neck cancers.  His research is toward a better understanding of how the body’s response to radiation-induced DNA damage and the associated repair processes can be modulated to enhance anti-cancer immunity.

Patient Care Philosophy

Every patient I have the privilege to care for is entitled to individualized, evidence-based treatment. Delivering optimal cancer care is one aspect of a wholistic treatment plan thoughtfully developed for each person with understanding and compassion.

Education and Training

Undergraduate: Middlebury College, Middlebury, VT

Master’s Degree: Harvard University, Boston, MA

Medical Degree: Mount Sinai School of Medicine, New York, NY

Doctoral Degree: Mount Sinai School of Medicine, New York, NY

Internship: Internal Medicine, Mount Sinai Hospital, New York, NY

Residency: Radiation Oncology, University of Washington, Seattle, WA

Published Works (out of 49)

PH Goff, L Riolobos, BJ LaFleur, MB Spraker, YD Seo, KS Smythe, …  “Neoadjuvant therapy induces a potent immune response to sarcoma, dominated by myeloid and B cells“.  Clinical Cancer Research 28 (8), 1701-1711. 2022

PH Goff, R Bhakuni, T Pulliam, JH Lee, ET Hall, P Nghiem.  “Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?“.  Cancers 13 (14), 3415. 2021

PH Goff, J Zeng, R Rengan, SK Schaub.  “Radiation and Modulation of the Tumor Immune Microenvironment in Non–Small Cell Lung Cancer“.  Seminars in Radiation Oncology 31 (2), 133-139. 2021

MM Cook, SK Schaub, PH Goff, A Fu, SY Park, DS Hippe, JJ Liao, …  “Postoperative, single-fraction radiation therapy in Merkel cell carcinoma of the head and neck“.  Advances in Radiation Oncology 5 (6), 1248-1254. 2020

G Vijayakumar, P Palese, PH Goff.  “Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma“.  EBioMedicine 49, 96-105. 2019

PH Goff, T Hayashi, W He, S Yao, HB Cottam, GS Tan, B Crain, …  “Synthetic toll-like receptor 4 (TLR4) and TLR7 ligands work additively via MyD88 to induce protective antiviral immunity in mice“.  Journal of Virology 91 (19), e01050-17. 2017

PH Goff, T Hayashi, L Martínez-Gil, M Corr, B Crain, S Yao, HB Cottam, …  “Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses“.  Journal of Virology 89 (6), 3221-3235. 2015

S Zha, C Guo, C Boboila, V Oksenych, HL Cheng, Y Zhang, …  “ATM damage response and XLF repair factor are functionally redundant in joining DNA breaks“.  Nature 469 (7329), 250-254. 2011

JH Wang, M Gostissa, CT Yan, P Goff, T Hickernell, E Hansen, …  “Mechanisms promoting translocations in editing and switching peripheral B cells“.  Nature 460 (7252), 231-236. 2009

AA Zarrin, PH Goff, K Senger, FW Alt.  “Sγ3 switch sequences function in place of endogenous Sγ1 to mediate antibody class switching“.  The Journal of experimental medicine 205 (7), 1567-1572. 2008

Research Interests

  • Skin cancer / Merkel cell carcinoma
  • DNA damage response
  • Anti-cancer immunity
  • Translational drug development

Research Support

  • ASCO Conquer Cancer Foundation
  • RSNA Research and Education Foundation
  • The Mark Foundation

Professional Involvement

  • Clinical Trials Committee, UW/FHCC